0.40Open0.40Pre Close109 Volume1.12K Open Interest2.00Strike Price4.01KTurnover326.63%IV21.72%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier10DDays to Expiry0.41Extrinsic Value100Contract SizeAmericanOptions Type0.5989Delta0.3656Gamma4.83Leverage Ratio-0.0216Theta0.0002Rho2.89Eff Leverage0.0013Vega
Gain Therapeutics Stock Discussion
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024
Gain Therapeutics presented new preclinical data for GT-02287 at the Society for Neuroscience 2024 conference. The data demonstrates disease-modifying activity in both GBA-1 and idiopathic Parkinson's disease models. Key findings include:
1. Persistent rescue of motor and cognitive function after GT-02287 discontinuation
2. Improved mitochondrial function and neuroprotection in GBA1-Parkins...
Gain Therapeutics, Inc. Mon, Sep 30, 2024, 7:00 AM 7 min read
Gain Therapeutics, Inc.
GT-02287 Increases Peripheral GCase Activity
GT-02287 Demonstrates CNS Exposure
shared via @Teddy123 Thanks!!
2 MINUTES AGO, 7:30 AM EDT
VIA GLOBENEWSWIRE
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
Gain Therapeutics (Nasdaq: GANX) has announced positive topline results from its Phase 1 clinical trial of GT-02287, a novel GCase-targeting small molecule therapy for Parkinson's disease.
The study, which enrolled 72 healthy volunteers, demonstrated that GT-02287 was safe and well-tolerated at a...
No comment yet